New River reiterated at buy by Merrill

Merrill Lynch analyst David Munno reiterated New River Pharmaceuticals Inc. at a buy rating after the company presented final phase 3 data showing that NRP104 had significant efficacy and was safe and tolerable, with no significant safety side effects. NRP104 also had a better safety profile than Adderall XR when comparing the phase 3 data for both. Merrill expects a smooth process toward final approval without the need for additional studies or more safety data. Shares of the Radford, Va., specialty pharmaceutical company were up $2.80, or 11.07%, at $28.10 on volume of 1,320,167 shares versus the three-month running average of 257,590 shares. (Nasdaq: NRPH)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.